Primary Record
Ertugliflozin
- In stock
- 4,209 g
- Purity
- 98.6 %
- CAS
- 1210344-57-2
Compound Identifiers & Properties
- CAS
- 1210344-57-2
- PubChem CID
- 44814423
- SMILES
- CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)CO)O)O)O)Cl
- Canonical SMILES
- CCOc1ccc(Cc2cc([C@]34OC[C@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)ccc2Cl)cc1
Names & Synonyms
- Ertugliflozin
- Steglatro
- 1210344-57-2
- ertugliflozina
- ertugliflozine
- PF-04971729
- ertugliflozinum
- Tube108
- C22H25ClO7
- RefChem:56924
- Ertugliflozin (Standard)
- Ertugliflozin [USAN:INN]
- PF04971729
- ERTUGLIFLOZIN [MI]
- MFCD21609259
- D0H4JC
- D0Q3VE
- ERTUGLIFLOZIN [INN]
- Ertugliflozin (USAN/INN)
- ERTUGLIFLOZIN [USAN]
- CHEMBL1770248
- UNII-6C282481IP
- cc-212
- SCHEMBL181047
- DTXSID40153120
- MK-8835
- ERTUGLIFLOZIN [WHO-DD]
- GTPL8376
- orb1302379
- Ertugliflozin/PF-04971729
- PF-04971729;Ertugliflozin
- 6C282481IP
- DTXCID4075611
- SCHEMBL29497947
- Ertugliflozin L-pyroglutamic acid
- A10BK04
- EX-A407
- CHEBI:188719
- MCIACXAZCBVDEE-CUUWFGFTSA-N
- Ertugliflozin (PF 04971729)
- ERTUGLIFLOZIN [ORANGE BOOK]
- AMY32613
- PF 04971729
- ABP000359
- BDBM50342885
- EBC-27095
- HY-15461R
- MSK177668
- PF-04971729 (Ertugliflozin)?
- s5413
- ZINC68197809
- AKOS025404928
- PF-04971729-00
- ACN-037560
- CCG-269087
- CS-0976
- DB11827
- RL00877
- (1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- AC-29007
- AS-35204
- BC638832
- CID:44814423
- FE137670
- HY-15461
- SID:210024075
- (1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- NS00072894
- PF 04971729-00
- PF-4971729
- Y0303
- J2.857.519J
- A11102
- A25468
- D10313
- W-5850
- EN300-7393259
- C570288
- SGLT2 inhibitor (oral, type 2 diabetes), Pfizer
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
- PF-04971729/PF04971729/
- Q27077223
- (1S,2S,3S,4R,5S)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- Empagliflozin Impurity 225 pound Ertugliflozin pound(c)
- B2693-452980
- 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
- beta-L-Idopyranose, 1,6-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-5-C-(hydroxymethyl)-
- (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
- (1s,2s,3s,4r,5s)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-hydroxymethyl-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
- beta-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
- Sodium glucose cotransporter-2 inhibitor (oral, type 2 diabetes), Pfizer
- (1S,2S,3S,4R,5S)-5-(4-CHLORO-3-((4-ETHOXYPHENYL)METHYL)PHENYL)-1-(HYDROXYMETHYL)-6,8-DIOXABICYCLO(3.2.1)OCTANE-2,3,4-TRIOL
- (1S,2S,3S,4R,5S)-5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo(3.2.1)octane-2,3,4-triol
- (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol
- (1S,2S,3S,4R,5S)-5-[4-Chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol
- (1S,5S)-1-(Hydroxymethyl)-5-[3-(4-ethoxybenzyl)-4-chlorophenyl]-6,8-dioxabicyclo[3.2.1]octane-2beta,3alpha,4beta-triol
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-|_-L-idopyranose
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-|A-L-idopyranose
- 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose; MK 8835; PF 04971729; PF 04971729-00; Steglatro
- 5-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1\r\n)octane-2,3,4-triol
- 813-709-2
- 863-196-4